In the present study, we found that G9a expression was increased in T2DM-BMSCs, and nanomoles of the G9a inhibitor, UNC0638, improved the osteogenic potential of T2DM-BMSCs. Here, EHMT2 is linked to type 2 diabetes mellitus.